Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer From Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer From Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of Directors") unanimously determined that the partial tender offer (the "Tender Offer") by Alternative Liquidity Index LP ("Alternative Liquidity") to acquire up to 10,000,000 common shares of Sinovac (the "Shares") for $0.03 per share in cash (the "Offer Price") is NOT advisable and is NOT in the best interests of the Company or its shareholders ("Shareholders"). Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.
中國領先的生物醫藥產品供應商科興生物股份有限公司(納斯達克股票代碼：SVA)(以下簡稱“科興生物”或“公司”)今天宣佈，其董事會(“董事會”)一致決定，另類流動資金指數有限責任公司(以下簡稱“另類流動資金”)以每股0.03美元現金收購科興生物1000萬股普通股(“股份”)的部分要約收購要約(以下簡稱“要約”)為不是可取的，也是不符合本公司或其股東(“股東”)的最佳利益。因此，董事會建議股東拒絕要約收購，並不根據要約以替代流動資金購買其股份。